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Antibody Against an Epitope on the
N-terminus of Meningococcal fHbp
David M. Vu, Rolando Pajon, Donald C. Reason & Dan M. Granoff
Children’s Hospital Oakland Research Institute, Oakland, CA 94609, U.S.A.
Meningococcal factor H binding protein (fHbp) is an important vaccine antigen for prevention of disease
caused by capsular group B strains. The protein has been sub-classified into three variant groups. Most
anti-fHbp antibodies are variant group-specific and recognize epitopes on the C-terminal domain. We
report a murine IgG1 mAb, JAR 41, which broadly cross-reacted with fHbp sequence variants from all
variantgroups.ThemAbboundtothesurfaceoflivemeningococciwithfHbpfromeachofthethreevariant
groups. In combination with second non-bactericidal anti-fHbp mAbs, JAR 41 elicited
complement-mediated bactericidal activity in vitro, and augmented passive protection against
meningococcal bacteremia in human fH transgenic rats. The epitope was located on a conserved region of
the N-terminal portion of the fHbp molecule opposite that of fH contact residues. The data underscore the
importance of broadly cross-reactive, surface-exposed epitopes on the N-terminal domain in the design of
protective fHbp vaccines.
F
actor H binding protein (fHbp) is an important antigen for vaccines being developed for prevention of
meningococcaldiseasecausedbycapsulargroupBstrains,forwhichcurrentlythereisnobroadlyprotective
vaccine (reviewed in
1,2). In mice and humans, vaccines containing recombinant fHbp elicited serum
bactericidal antibody activity
3–7, which is a serologic surrogate of protection against developing meningococcal
disease
8–10. Based on amino acid sequence homology and antigenic cross-reactivity, fHbp has been sub-classified
into two sub-families
11 or three variant groups
12. fHbp also can be classified into modular groups based on
different combinations of five variable segments, each of which is encoded by genes from one of two lineages
13.
In general, bactericidal activity of anti-fHbp antibodies was largely confined to meningococcal strains with fHbp
amino acid sequence variants from the same variant group or sub-family as that of the vaccine antigen
7,12,14.
In previous studies, our laboratory has characterized panels of anti-fHbp mAbs prepared in mice immunized
with fHbp from variant groups 1, 2 or 3
15,16. While an occasional mAb reacted with fHbp sequence variants from
more than one variant group, to date, none of the mAbs reacted with sequence variants from all three variant
groups. In this study, we describe a new anti-fHbp mAb, designated JAR 41, which was isolated from a human
factor H (fH) transgenic mouse that had been immunized with a recombinant fHbp from variant group 1
17. The
new mAb recognized a surface-exposed, broadly cross-reactive epitope present in all fHbp sequence variants
tested from variant groups 1, 2 or 3. Thus, JAR 41 may be useful for developing assays to measure strain
expression of fHbp, which is an important determinant of susceptibility to anti-fHbp bactericidal activity
18–21.
Information on the JAR 41 epitope also may be important for the design of improved broadly protective fHbp
vaccines
14,22.
Results
Anti-fHbp mAb JAR 41 is broadly cross-reactive. By ELISA, JAR 41 had similar concentration-dependent
binding to fHbp ID 1 (variant group 1) as that of a control anti-fHbp, JAR 5, which is specific for variant group 1
(Figure 1a). Two other anti-fHbp mAbs, JAR 11 and JAR 35, which bind fHbp from variant groups 2 and 3, but
not from group 1, served as negative IgG controls. JAR 41 also showed similar concentration-dependent binding
to fHbp ID 77 (variant group 2) and fHbp ID 28 (variant group 3) as that of the respective positive controls,
variant group-specific mAbs (Figures 1b and 1c, respectively). There was no reactivity of these two proteins with
JAR 5, which was specific for fHbp variant group 1.
As of December 2011, more than 500 unique fHbp amino acid sequence variants had been deposited in the
public database, http://pubmlst.org/neisseria/fHbp/. To select sequence variants representative of fHbp diversity
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phylogenic analysis of 531 sequences in the public database in the
form of a network diagram produced using the program SplitsTree
4
23 (Figure 2a). Each unique sequence is represented by a ‘‘twig’’
(node), which are distributed on the network into two sub-families,
AandB,asdescribedbyFletcheretal
7,orthreevariantgroups,1,2or
3, as described by Masignani et al
12. Sub-family A contains the
sequences in variant groups 2 and 3, and sub-family B contains the
sequences in variant group 1. The proteins also can be classified into
ten modular groups based on the respective lineages of five variable
segments
13,18.
We selected 21 amino acid sequence variants representative of the
known fHbp amino acid sequence diversity for expression of recom-
binant proteins for testing JAR 41 reactivity (Table 1). This panel
included variants from both sub-families A and B, all three variant
groups
12, and all ten modular groups
13,18 (Figure 2b). Note that fHbp
ID 283, which is a natural hybrid of variant groups 1 and 3, has A, B,
andCsegmentsfromlineage2,andDandEsegmentsfromlineage1.
This variant was assigned to a new modular group (X).
JAR 41 showed similar respective concentration-dependent bind-
ingwithalloftheaminoacidsequencevariantsinvariantgroups1,2
and3(Figure3a–c),andwithtwonaturalhybrids,ID207andID283
(Figure3d).BindingwasspecificforfHbpinthatJAR41didnotbind
to two unrelated recombinant meningococcal surface proteins,
NadA and GNA1030 (Figure 3e). Also, with each of the sequence
variantstestedbyELISA,weincludednegativecontrolIgGanti-fHbp
mAbsthatwerespecificforfHbpsfromheterologousvariantgroups,
which showed negligible binding to the sequence variant tested for
binding with JAR 41 (See for example, Figure 1).
TheJAR41epitopeisexposedonthesurfaceoflivemeningococci.
By flow cytometry, JAR 41 bound to the surface of live bacteria from
N.meningitidisstrains.Figure4acomparesbindingofJAR41(25mg/
ml) to wild-type group B strain H44/76 (fHbp ID 1, variant group 1)
andanisogenicmutantofstrainH44/76withlowerfHbpexpression
(H44/76-LE).Thereis,4-foldlowerbindingwiththemutantstrain.
There was no detectable binding to either strain with a control IgG
mAb,JAR11(specific forfHbpsinvariantgroups2or3).Binding of
an anti-PorA mAb was similar with both the wild-type and mutant
(Figure 4b), which is evidence that similar numbers of wild-type and
mutant cells were tested for JAR 41 binding.
We next tested binding of JAR 41 to strains H44/76 and its iso-
genic mutant using a range of mAb concentrations (Figures 4c and
4d, respectively). As little as 0.2 mg/ml of JAR 41 showed significant
binding to the H44/76-WT or -LE mutants over that of background
binding, which was determined by testing 25 mg/ml of JAR 41 with a
H44/76 fHbp knockout mutant (light gray shaded area). JAR 41 also
bound to the surface of group B strains 8047 (fHbp ID 77, variant
group2)andM1239(fHbpID28,variantgroup3)(Figures4eand4f,
respectively). For each of these strains the respective JAR 41 binding
wassimilarwhentestedatthetwohighestconcentrations(5mg/mlor
25 mg/ml for 8047, or 5 and 50 mg/ml for M1239 [grey-shaded area
and solid lines, respectively]). Strain 8047 also was tested with lower
concentrations of the mAb. Binding above that of the IgG negative
control (an IgG anti-fHbp mAb specific for variant group 1) was
detected with as little as 0.2 mg/ml of JAR 41.
Figure 1 | Binding of anti-fHbp mAb JAR 41 to recombinant fHbp in
variant groups 1, 2 or 3. Grey circles, JAR 41. Open triangles, JAR 5. Xs,
JAR 11. Open squares, JAR 35. Panel a, fHbp ID 1 from variant group 1.
Panelb,fHbpID77fromvariantgroup2.Panelc,fHbpID28fromvariant
group 3.
Figure 2 | Relatedness of unique fHbp amino acid sequences. Network
analysis illustrating the relatedness of unique fHbp amino acid sequences,
asgenerated usingthe programSplitsTree
23. Panela, therelatedness of531
unique fHbp amino acid sequences available from the public database
www.pubmlst.org.Each‘‘twig’’(node)representsauniquesequence.Sub-
families, as described by Murphy et al
11; variant groups as described by
Masignani et al
12, and modular groups (denoted using roman numbers as
described by Beernink and Granoff
13. Modular Group X is a new group
reported in this work. Panel b, the relatedness of the 21 fHbp sequence
variants, which were selected for production of recombinant proteins (See
Table1).Eachfilled circle representsaunique sequence variant designated
byfHbpIDnumberfromthepublicdatabasehttp://pubmlst.org/neisseria/
fHbp.
www.nature.com/scientificreports
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with second anti-fHbp mAbs. JAR 41 was not bactericidal when
tested individually at concentrations of up to 100 mg/ml against any
of the four test strains (H44/76-WT [Figure 5a], the H44/76 LE
mutant [Figure 5b], 8047 [Figure 5c] or M1239 [data not shown]).
Activation of the classical complement pathway by IgG requires
binding of two IgG mAbs to appropriately spaced epitopes such
that the respective IgG Fc regions can engage C1q
24. When an
individual mAb binds to a sparse antigen, there may be insufficient
immune complex formed to activate bacteriolysis, whereas com-
binations of more than one mAb may be sufficient
24. When tested
incombinationwithothernon-bactericidalanti-fHbpmAbsspecific
for fHbp in variant group 1, JAR 41 elicited cooperative bactericidal
activity against strains H44/76 (Figure 5a) or the H44/76 LE mutant
with lower fHbp expression (Figure 5b). In contrast, JAR 41 was not
bactericidalincombinationwithanti-fHbpmAbsspecificforvariant
groups2or3whentestedagainststrains8047(fHbpvariantgroup2,
Figure5c)orM1239(fHbpvariantgroup3,datanotshown).Bothof
these strains were susceptible to bactericidal activity elicited by anti-
fHbp mAb JAR 4 when tested with the anti-fHbp mAbs specific for
variantgroups2or3(forexample,JAR41JAR11orJAR13against
strain 8047, Figure 4c).
JAR 41 augments passive protective activity of anti-fHbp mAb
JAR 5 against experimental meningococcal bacteremia. Binding
of human fH to the surface of meningococci down-regulates
complement activation, which enables the organism to evade host
defenses
25–27. Binding is specific for human fH
27. We recently
developed a human fH transgenic infant rat model to investigate
the effect of human fH on meningococcal bacteremia
28. After
challenge of wild-type rats, strain H44/76 was cleared rapidly from
thebloodstreamwhereasthepresenceofhumanfHinthetransgenic
animals enhanced bacteremia. In the present study we used the
human fH transgenic rat model to investigate the ability of JAR 41
given individually or in combination with other non-bactericidal
anti-fHbp mAbs to confer passive protection against bacteremia
caused by challenge with wild-type group B strain H44/76.
Despite lack of bactericidal activity in vitro, pretreatment of
humanfHtransgenicinfantratswith25mgofJAR5conferredpartial
protection against bacteremia, as evidenced by a lower geometric
mean CFU/ml in blood obtained 6 hrs after IP challenge, compared
to that of control rats that received PBS (p,0.05, Experiments 1 and
2,Figure6).Incontrast,25mg/ratofJAR41didnotconfersignificant
protection in either experiment (p.0.05). To determine whether
JAR 41 could augment JAR 5 protective activity, both antibodies
(12.5 mg/rat of each mAb) were given in combination to groups of
human fH transgenic infant rats. In both experiments, none of these
animalshadbacteremia6 hrsaftertheIPchallenge.InExperiment2,
in which we tested larger numbers of animals, the augmentation of
protection by the combination of JAR 41 and JAR 5 was statistically
significant (6 of 9 with bacteremia in the JAR 5 or JAR 41 alone
groups, vs. 0 of 8 in the JAR 51JAR 41 combination group,
p50.009).
JAR41recognizesanepitopethatoverlapsthatofanti-fHbpmAb
JAR 4. While the combination of JAR 4 with JAR 5, or JAR 4 with
mAb502,wasbactericidalagainstgroupBstrainH44/76,JAR41was
notbactericidal incombinationwith JAR4 (Figure5a).One possible
explanation was that JAR 4 and JAR 41 recognized overlapping
epitopes. To investigate this question, we measured the ability of
JAR 4 to inhibit binding of alkaline phosphatase (AP)-conjugated
JAR 41 to fHbp (Supplemental Figure S1a). The positive control,
unconjugated JAR 41, gave .95% inhibition of binding while the
negative control, unconjugated JAR 5, gave ,5% inhibition. At the
highest concentration of mAb tested (100 mg/ml), JAR 4 gave ,70%
inhibition of binding of AP-JAR 41 to fHbp. We also measured the
Table 1 | Recombinant fHbp amino acid sequence variants tested for JAR 41 binding
Source Strain
(fHbp gene) fHbp ID
1 Sub-family
2
Variant
Group
3
Modular
Group
4
Control Anti-fHbp mAb Reactivity
5
JAR 1 JAR 4 JAR 3/5
6 mAb 502 JAR 11 JAR 13 JAR 31 JAR 35
MC58 1 B 1 I 1 11 1 222 2
Synthesized
7 2B 1 1 1 11 2 222 2
SK068 4 B 1 I 1 11 1 222 2
M6190 6 B 1 I 2 12 2 222 2
Mali 29/07 9 B 1 I 1 11 1 222 2
SK105 13 B 1 I 1 11 1 222 2
NZ98/254 14 B 1 I 2 11 2 222 2
Uganda 6/07 74 B 1 I 2 11 2 222 2
NM452 15 B 1 IV 2 21 2 222 2
CDC-1573 55 B 1 IV 2 22 2 222 2
RM1090 22 A 2 III 2 12 2 211 1
SK139 19 A 2 VI 2 12 2 111 2
8047 77 A 2 VI 2 12 2 111 2
M1239 28 A 3 II 2 22 2 211 1
2040 111 A 3 II 2 22 2 211 2
N27/00 45 A 3 V 2 22 2 111 2
S3032 79 A 3 V 2 22 2 111 2
MA-5756 67 A 3 VIII 2 22 2 211 1
19498 175 A 3 IX 2 22 2 111 2
0167/03 207 A/B 1/2 VII 2 11 2 221 2
Synthesized
7 283 A/B 1/3 X 2 22 2 222 2
1Amino acid sequence variant in the public database, http://pubmlst.org/neisseria/fHbp/.
2Sub-family as described by Murphy et al
11.
3Variant group as described by Masignani et al
12.
4Modular groups as described by Beernink and Granoff
13 and Pajon et al
18.
5Positivereactivity,OD.1inanELISAwhentestedat0.1mg/ml;negativereactivity,OD,0.3whentestedat1mg/ml.JAR1,JAR4,JAR3andJAR5
15,16,andmAb502
31,37arefrommiceimmunizedwith
fHbpID1(variantgroup1).JAR11andJAR13arefromamouseimmunizedwithfHbpID16invariantgroup2
16,42,andJAR35(REF:Beernink2008)andJAR31wasfromamouseimmunizedwithfHbpID
28 (variant group 3) (unpublished data of D.M.G.).
6JAR 3 and JAR 5 recognize overlapping epitopes involving Arg at position 121 of fHbp ID 1
16.
7Genes encoding fHbp IDs 2 and 283 were synthesized from nucleic acid sequences of fHbp alleles 2 and 333, respectively, obtained from public database, http://pubmlst.org/neisseria/fHbp/.
www.nature.com/scientificreports
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unconjugated JAR 4 (IgG2a) using an AP-conjugated secondary
antibody that was specific for IgG2a (Supplemental Figure S1b).
JAR 41 gave .95% inhibition of binding of JAR 4 to fHbp. The
ability of JAR 41 and JAR 4 to inhibit binding of each other to
fHbp implied that the respective epitopes overlapped.
The fHbp epitope recognized by JAR 41 is eliminated by
substitution of Ala for Asp at residue 25 in fHbp. We used a
mutant fHbp ID 1 library displayed on the surface of yeast to
identify amino acid residues that potentially affect JAR 41 binding.
The yeast library was sorted to select yeast clones that had lost their
ability to bind JAR 41, but which retained their ability to bind JAR 3
(which verified surface-expression of the construct). Individual JAR
41-negative/JAR 3-positive yeast colonies were expanded and the
fHbp gene inserts were sequenced. After eliminating sequences
containing large deletions or multiple amino acid substitutions, we
aligned the predicted amino acid sequences of 13 full-length mutant
fHbp genes (Supplemental Figure S2). The mutations that abolished
JAR 41 binding in the yeast library included three substitutions for
Asp at position 25 (D25G, D25H, D25A), one substitution for Lys at
position 27 (K27N), and one substitution for His at position 26
(H26N, which was present in combination with D25A). Substitutions
at residue K27 and, to a lesser extent, D25A, corresponded to the region
of the N-Terminal domain of fHbp previously shown to be important
for binding of JAR 4 to fHbp
29.
To confirm the importance of the individual residues on binding
of JAR 41, we used site-directed mutagenesis to prepare mutant
recombinant proteins with individual alanine substitutions at these
positions. While the D25A mutation abolished binding of JAR 41
(Figure7a,circles with dashedline),therewasnosignificanteffectof
the K27A or H26A substitutions on JAR 41 binding to the recom-
binant mutant proteins. It is possible that the lack of an effect of
K27A is explained by the different substituted residue (K27N in
yeast, vs. K27A in the recombinant protein). The lack of an effect
of H26A can be explained by the absence of the D25A substitution,
since in yeast the mutant H26A fHbp that did not bind JAR 41 also
contained D25A, which individually was sufficient to eliminate JAR
41 binding.
Disruption of JAR 41 binding with the D25A mutant was not a
result of disruption of overall protein folding since the recombinant
D25A mutant protein retained epitopes needed for bindingwith two
control anti-fHbp mAbs, JAR 1 and JAR 5 (Figures 7c and 7d,
respectively). JAR 1 recently was shown to recognize an epitope
involving residue 204
30, and JAR 5 recognized an epitope involving
residues 121 and 122
16 (Figure 7d). Interestingly, the D25A substi-
tutionalsohadminimaleffectonbindingofJAR4(Figure7b),which
has an epitope on the N-terminal domain
29 that overlaps that of JAR
41.
Discussion
Bindingofmostpreviouslydescribedanti-fHbpmAbswaslimitedto
sequence variants belonging to the same variant group or sub-family
as that of the vaccine antigen
15,16,31. To our knowledge only one anti-
fHbp mAb (MN86-994-11) was reported to cross-react with fHbp
variantsfromallthreevariantgroups
32.Insufficient details,however,
were provided on this mAb to determine the actual breadth of react-
ivity,functionalactivity,oraminoacidresiduesaffectingtheepitope.
In the present study, the ability of JAR 41 to bind equally well by
ELISA to all 21 recombinant fHbp sequence variants tested, and to
bindbyflowcytometry tothesurface of livebacteria withfHbpfrom
variant groups 1, 2, or 3 indicated that the epitope was nearly uni-
versal, and was surface-exposed and accessible to antibody.
The fHbp molecule consists of two domains of antiparallel b-
strands connected by a linker
33,34. The epitope recognized by JAR
41 appears to be located on the N-terminal domain since a single
amino acid substitution, Ala for Asp at residue 25 of fHbp ID 1
(D25A), eliminated JAR 41 binding. Among the 531 known amino
acid sequence variants in the public fHbp peptide database (http://
pubmlst.org/neisseria/fHbp/, as of December 2011), Asp at residue
25 was invariant. Further, the adjacent residues in this region of the
N-terminal domain also are highly conserved.
We determined that the JAR 41 epitope overlapped that of a prev-
iously reported anti-fHbp mAb, JAR 4, which was specific for fHbp
in variant groups 1 and 2
29. The molecular architecture of fHbp is
modular with five variable segments, designated A, B, C, D and E,
each of which is derived from one of two lineages
13. Among the 21
fHbp sequence variants tested (Supplemental Figure S3), JAR 4
bound only to variants containing ‘‘A’’ segments derived from lin-
eage 1 (previously referred to as alpha lineage
13). In contrast, JAR 41
boundtoallvariantstestedwithAsegmentsfromlineage1orlineage
2 (previously referred to as beta lineage).
The residues of fHbp in contact with fH have been identified in a
crystalstructureoffHbpinacomplexwithafragmentoffH
35.ThefH
contact residues were located on a surface opposite that containing
Asp25, which affected the JAR 41 epitope, and Asp25 and Lys27,
which affected the JAR 4 epitope (See cartoon, Supplemental Figure
S4). The respective locations were consistent with ELISA data show-
ingthatneitherJAR4
16,29norJAR41mAbinhibitedbindingoffHto
fHbp (data not shown).
JAR 41 individually did not elicit human complement-mediated
bactericidal activity, which is typical of most reported murine anti-
fHbp mAbs
15,16,24,29. fHbp is relatively sparsely distributed
15, and it is
possiblethatthedistancebetweenmostofthefHbpmoleculesonthe
bacterial surface exceeds that required for optimal engagement of
Figure 3 | BindingofJAR41to21fHbpsequencevariantsasmeasuredby
ELISA. Panel a, recombinant fHbps from variant group 1. Panel b,
recombinant fHbps from variant group 2. Panel c, recombinant fHbps
from variant group 3. Panel d, natural hybrids between variant groups 1
and 2, or 1 and 3. Panel e, solid lines, Data from JAR 41 binding to all 21
recombinant sequence variants (solid lines); or with with negative control
recombinant proteins NadA and GNA1030 (dashed lines).
www.nature.com/scientificreports
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antibodiesthatrecognizeappropriately spacednon-overlappingepi-
topesmaypermitmoreefficientengagementofC1qandactivationof
classical complement pathway bacteriolysis
15,16,24,29. Since binding of
fH to N. meningitidis increases resistance of the organism to
complement-mediated killing
25,26, the ability of at least one of the
anti-fHbp mAbs in the pair to inhibit fH can increase mAb bacter-
icidal activity
36.
While JAR 41 bound to the surface of strains H44/76, 8047 and
M1239 with fHbp in variant groups 1, 2 or 3, respectively (Figure 4),
the mAb elicited cooperative complement-mediated bactericidal
activity only against strain H44/76 with fHbp in variant group 1,
andanisogenicmutant,H44/76-LEwithlowerfHbpID1expression
(Figure 5). The amount of expression of fHbp variant group 1 by the
mutant appeared to be similar to that of the two strains with fHbp in
variant groups 2 or 3 that were resistant to anti-fHbp JAR 41 coop-
erative bactericidal activity. Most likely the resistance of these two
teststrainsreflectedtestingbactericidalactivitywithdifferentsecond
anti-fHbp mAbs, whichwere specific forfHbp invariant groups2 or
3, than those used to test the strains with fHbp variant group 1.
Conceivably, different proximity and/or spatial orientations of JAR
41boundincombinationwithJAR5ormAb502instrainH44/76,as
Figure 4 | Binding of mAbs to live N. meningitidis strains as measured by flow cytometry. Panel a, Comparison of JAR 41 binding (25 mg/ml) to wild-
typestrainH44/76(H44/76-WT, solidblackline)withfHbpID1invariantgroup1,oranisogenic mutantwithlowerexpressionoffHbp ID1(H44/76-
LE,bluedashedline).Solidgreenline,H44/76-WTincubated with25mg/mlofanegativecontrolIgGmAb(JAR11,specificforfHbpinvariantgroups2
and 3); green-shaded area, H44/76-LE incubated with JAR 11. Panel b, binding of a control anti-PorA mAb. Orange line, H44/76-WT; orange-shaded
area, H44/76-LE. Panels c-f, Concentration-dependent binding of JAR 41 with strain H44/76-WT (panel c), mutant strain H44/76-LE (panel d), strain
8047withfHbpinvariant group2(panele),orM1239withfHbpinvariant group3(panelf).Panelsc,dande,thickblackline,25mg/mlofJAR41;dark
grey-shaded area, 5 mg/ml; dashed black line, 1 mg/ml; thin black line, 0.2 mg/ml; light grey-shaded area, 25 mg/ml JAR 41 with a negative control H44/76
fHbp knock-out mutant; solid blueline, 25 mg/ml ofJAR 5,whichis specific for fHbp invariant group1 andanegative control mAb forvariants 2and 3.
Panel f, thick black line, 50 mg/ml of JAR 41 with wild-type strain M1239 with fHbp in variant group 3; dark shaded area, 5 mg/ml of JAR 41 (lower
concentrations of JAR 41 were not tested); blue line, 50 mg/ml of JAR 5 (specific for fHbp variant group 1); Light gray shade area, 50 mg/ml of JAR 41
incubated with M1239 fHbp knock-out mutant.
www.nature.com/scientificreports
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more efficient engagement of C1q and activation of the classical
complement pathway with strain H44/76.
In the present study, we used a recently described human fH
transgenic infant rat model
28 to investigate the ability of JAR 41,
individually or in combination with JAR 5, to confer passive protec-
tion against meningococcal bacteremia caused by group B strain
H44/76. We chose to use the transgenic infant rat model because
binding of fH to N. meningitidis is specific for human fH
27,28. Thus,
measuringtheabilityofanti-fHbpmAbstoconferpassiveprotection
in the transgenic model likely provided information relevant to
protection in humans where bound human fH can down-regulate
complement activation on N. meningitidis.
Passive administration of JAR 5 conferred partial protection
against meningococcal bacteremia in the transgenic rats (Figure 6).
This protective activity was of interest since JAR 5 individually did
not elicit human complement-mediated bactericidal activity
(Figure 5) but in previous studies was shown to block binding of
human fH to fHbp
16. In contrast, JAR 41, which was not bactericidal
and which did not block fH binding, was not protective against
bacteremiainthetransgenic ratmodel.JAR41,however,augmented
protective activity of JAR 5 (sterile blood cultures in all therats given
the combination). This result was consistent with the ability of JAR
41 to elicit cooperative complement-mediated bactericidal activity
when tested with JAR 5.
Figure 5 | Cooperative bactericidal activity elicited by JAR 41,
individually or in combination with second anti-fHbp mAbs. Panel a,
strainH44/76(fHbpID1,variantgroup1).Panelb,mutantofstrainH44/
76 engineered to have lower expression of fHbp ID 1 as that of the wild-
type strain(See Figure 4a).Panel c, strain 8047(fHbp ID 77,variant group
2). BC50%, concentration of mAb (mg/ml) resulting in 50% decrease in
CFU/mlafter1 hrincubationwithhumancomplement,comparedtotime
0. The combinations contained 151 mixtures (i.e, BC50% of 1 mg/ml
contained 0.5 mg/ml of each of the mAbs in the combination). The anti-
capsular mAb (SEAM 12)
41 or anti-PorA mAbs (P1.7, panels a and b; or
P1.2, panel c) served as positive controls. Error bars represent range of
results from two to three independent assays.
Figure 6 | JAR 41 augments passive protective activity of anti-fHbp mAb
JAR 5 against bacteremia caused by group B strain H44/76 in human fH
transgenic infant rats. Panel a, Experiment 1, 8- to 9-day old rats
challenged IP with 4900 CFU/rat; Panel b, Experiment 2, 6- to 7-day old
ratschallengedIPwith760 CFU/rat.Inbothexperiments,ratsweregivena
total dose of 25 mg of mAb or phosphate buffered saline alone (PBS,
negative control) 1 hr before the bacterial challenges. The combination
contained 12.5 mg of each mAb. Blood cultures were obtained 6 hrs after
challenge. Compared to PBS, rats given JAR 5 alone had a lower geometric
mean CFU/ml (Experiment 1, p50.04 and Experiment 2, p,0.03)) but
there was no protection by JAR 41 alone (p.0.05). In Experiment 2, the
combination of JAR 41 and JAR 5 (0/8 with bacteremia) had greater
protective activity than JAR 5 alone (6 out of 9 with bacteremia, p50.009,
Fisher’s exact test). ND, not done.
Figure 7 | Effect of amino acid substitutions on binding of mAbs to
recombinant fHbp. (Xs with solid line), wild-type fHbp ID 1;
(Open squares with dotted line), H26A; (Open triangles with dashed
line), K27A; (Open circles with solid line), D25A. Panel a, JAR 41.
Panel b, JAR 4. Panel c, JAR 1. Panel d, JAR 5.
www.nature.com/scientificreports
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broadly cross-reactive, surface-exposed epitope on the N-terminal
domain of fHbp from variant groups 1, 2 and 3. The mAb elicits
cooperative human complement-mediated bactericidal activity in
combination with other non-bactericidal anti-fHbp mAbs, and aug-
ments passive protective activity against meningococcal bacteremia.
The JAR 41 epitope overlapped that of JAR 4, which also had coop-
erative bactericidal activity but was specific for fHbp from variant
groups 1 and 2. Collectively, the data demonstrate the importance of
including cross-reactive epitopes in N-terminal domain of fHbp in
the design of optimally protective fHbp vaccines.
Methods
Production of anti-fHbp mAb JAR 41. A human fH transgenic BALB/c mouse was
immunized with three injections of a recombinant fHbp vaccine as part of a previous
study
17. The fHbp sequence variant was from variant group 1 and assigned ID 1 as
designatedinthepublicfHbppeptidedatabaseathttp://pubmlst.org/neisseria/fHbp/.
The mouse received three injections of the vaccine, IP, along with aluminum
hydroxideadjuvantfollowedbyafourthinjectionwithoutadjuvant.Splenocyteswere
isolated three days later for fusion to the mouse myeloma cell line P3X63-Ag8.653
using established methods
15. Cells were plated into 96-well plates. After two weeks of
incubation, cell culture supernatants were tested for reactivity to recombinant fHbp
ID 1 by ELISA (see below). Cells from positive wells were expanded, cloned by
limiting dilution, and the supernatants confirmed for reactivity to fHbp. The cloning
was repeated 2 times to ensure monoclonality.
Control anti-fHbp mAbs. The following murine anti-fHbp mAbs were used as
controlsindifferentbindingandfunctionalassays:JAR1(IgG3),JAR3(IgG3),JAR4
(IgG2a), JAR 5 (IgG2b)
15,16, and mAb502 (IgG2a)
31,37 were from mice immunized
with fHbp ID 1 in variant group 1; JAR 11 (IgG2a) and JAR 13 (IgG2a) were from a
mouse immunized with fHbp ID 16 in variant group 2
16, and JAR 31 (IgG2b)
(Unpublished data of DMG) and JAR 35
16 were from a mouse immunized with fHbp
ID 28 in variant group 3.
Purification of recombinant fHbp. We prepared 21 different recombinant fHbp
amino acid sequence variants from variant groups 1, 2 or 3 (Table 1) as previously
described
30. The proteins were expressed from the T7 promotor using the E. coli
plasmid pET21b (Novagen, Madison, WI) as described previously
16. The
recombinantproteinswerepurifiedbyimmobilizedmetalionchromatographyusing
Ni-NTA agarose (Qiagen, Valencia, CA) as described previously
16. Purified fHbps
weredialyzedagainstPBS,sterilizedbyfiltration(Millex0.22mm;Millipore,Billerica,
MA), and stored frozen at 230uC. The protein concentrations were determined by
UV absorbance (Nanodrop 1000, Wilmington, DE) based on the extinction
coefficient calculated from the amino acid sequence
38.
Anti-fHbp ELISA. Binding of anti-fHbp mAbs to recombinant fHbp (rfHbp) was
measured by ELISA, which was performed as described previously
36 with minor
modifications.Inbrief,2mg/mlofpurifiedrecombinantfHbpdilutedinPBSwasused
to sensitize the microtiter plates. After blocking, serial dilutions of the mAbs were
added and incubated at 4uC overnight. The wells were washed and bound antibody
was detected with goat anti-mouse IgG conjugated with alkaline phosphatase. The
ability of JAR 41 to inhibit binding of fH to fHbp was also measured by ELISA as
previously described
36.
Epitopemappingusingyeastdisplay.Randomlymutatedsequences offHbpallele1
(http://pubmlst.org/neisseria/fHbp/), which encodes fHbp amino acid sequence
variant ID 1, were generated by error-prone PCR. In brief, MnCl2 concentrations
were titrated and conditions selected such that the average number of nucleotide
substitutions per fHbp gene copy resulted in 1 to 3 amino acid substitutions. The
fragments were ligated into pUC18, expanded in E. coli, excised, inserted into
theyeastexpressionvectorpYD1(Invitrogen,Carlsbad,CA),andtransfectedintothe
yeast EBY100 strain (Invitrogen) to form the mutated fHbp expression library.
The mutated fHbp peptides were displayed on the surface of yeast as Aga2 fusion
proteins
39,40. The library was expanded overnight at 30uC, transferred into galactose-
containing YNB medium (Yeast Nitrogen Base w/o amino acids [Difco]) to induce
recombinantproteinexpression,andincubatedfor48 hrsat20uC.Bulkyeastcultures
were simultaneously stained with anti-fHbp mAb, JAR 41, which was detected with
FITC-conjugated antibody to mouse IgG, and a chimeric human IgG1 mouse anti-
fHbp mAb, JAR 3
36, which was detected with DyLight 649-conjugated antibody to
human kappa light chain. JAR 3 and JAR 41 recognized non-overlapping epitopes as
evident by lack of inhibition of binding by ELISA of either mAb to fHbp ID 1 by the
other mAb (data not shown). The yeast cultures were sorted by flow cytometry
(FACSaria, BD) to select yeast clones that had lost their ability to bind JAR 41, but
which retained the ability to bind JAR 3 (which verified surface-expression of the
construct). The sorted yeast were plated and incubated at 30uC to isolate single
colonies. The individual clones were re-grown, their binding profiles verified by flow
cytometry, and the sequence of the respective fHbp insert determined to identify
amino acid substitutions that had resulted in the loss of the JAR 41 epitope.
Approximately20JAR41-negative/JAR3-positiveyeastcloneswereanalyzedandthe
sequences of theirinserts aligned toidentifyaltered residues thatled tolossofJAR 41
binding.
Construction of site-specific mutants. Recombinant fHbp mutants with single
amino acid substitutions were constructed using the QuikChange II kit (Stratagene,
La Jolla, CA) using the manufacturer’s protocols as previously described
16.T h e
mutagenesis reactions were transformed into chemically competent E. coli DH5a
(Invitrogen, Carlsbad, CA) and independent mutant clones were verified by DNA
sequencing (Davis Sequencing, Davis, CA).
Flow cytometry. Binding of the murine mAbs to the surface of live encapsulated
bacteria was measured by flow cytometry, which was performed as described
previously
36. The group B test strains were H44/76 (B:15:P1.7,16; ST-32) with fHbp
ID 1; a previously described isogenic mutant, which had been engineered to have
decreased expression of fHbp ID 1
19; 8047 (B:2b:P1.5-1, 2-2; ST-8), which expressed
fHbp ID 77 in variant group 2; and M1239 (B:14:P1.23,14; ST-41/44), which
expressed fHbp ID 28 in variant group 3. The bacterial cells were grown in Mueller
Hintonbrothculture,harvestedbycentrifugation,washed,andresuspendedinbuffer
as described elsewhere
36.
Serum bactericidal assay. Human complement-mediated bactericidal activity was
measured as previously described
17 using group B strains H44/76, 8047 and M1239
described above. The complement source was serum from a healthy adult who
participated in a protocol that was approved by the Children’s Hospital Oakland
Institutional Review Board (IRB). Written informed consent was obtained from the
subject. The serum had normal total hemolytic complement activity and no
detectable serum bactericidal antibodies against the test strains. The serum was
depleted of IgG using a protein G column (HiTrap Protein G, GE Life Sciences,
Piscataway, NJ) as previously described
17 to remove non-bactericidal antibodies that
might augment anti-fHbp mAb activity
4.
The bactericidal activity (BC50%) was defined by the mAb concentration that
resultedina50%decreaseinCFU/mlafter60-minincubationinthereactionmixture
compared with CFU/ml in negative control wells at time zero.
Passive protective activity against bacteremia. Details of the human fH transgenic
rat meningococcal bacteremia model have been recently described
28.F o r
measurementofpassiveprotectiveactivity,attime0humanfHtransgenicrats,ages8
to 9 days (experiment 1) or 6 to 7 days (experiment 2), were administered 25 mgI Po f
anti-fHbp mAb JAR 5 or JAR 41, or a combination of JAR 5 1 JAR 41 (12.5 mgo f
each). Control rats received buffer alone (phosphate buffered saline, PBS) or 12.5 mg
of an anti-PorA mAb (P1.7, experiment 1 only). Total volume of mAb or buffer for
each animal was 100 ml. At 1.5 hrs, animals were challenged IP with 4900 CFU
(experiment 1) or 760 CFU (experiment 2) of group B strain H44/76. At 7.5 hrs,
blood samples were obtained by cardiac puncture into syringes containing 25 U
heparin. 1, 10, and 200 ml aliquots of each blood sample were spread onto chocolate
agar plates, which were then incubated overnight at 37uCi n5 %C O 2. Colony counts
were obtained the following day to determine CFU/ml. The lower limit of detection
was 5 CFU/ml.
Statistical analyses. Statistical analyses were performed using Prism for Mac version
5.0d (GraphPad Software, La Jolla, CA). Comparisons of the proportions of rats that
developed bacteremia after pre-treatment with different mAbs or PBS were
performed using the Fisher exact test. For the purpose of calculating the geometric
meanCFU/mlofblood,sterilebloodcultureswereassignedavalueofhalfofthelower
limit of detection (i.e., ,5 CFU/ml was assigned a value of 2.5 CFU/ml).
ComparisonsofthegeometricmeanCFUofbacteriapermlofbloodbetweenanytwo
groups ofratswereperformedonlog-transformed values using theStudent t-test. All
probability values reported are two-tailed.
Livevertebrateexperiments.Allexperimentsinmiceandinfantratswereperformed
in strict accordance with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health, U.S.A. The protocols were
approved by the Children’s Hospital & Research Center at Oakland Institutional
Animal Care and Use Committee. Blood collection was performed under anesthesia,
and all efforts were made to minimize suffering.
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